There is also evidence of a negative effect of obesity on the efficacy of an adjuvant aromatase inhibitor in women with hormone receptor-positive breast cancer due to an increased peripheral aromatase inhibitor [97,99]. The gene discussed is CYP19A1; the disease is obesity due to melanocortin 4 receptor deficiency.